WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Five Prime Therapeutics, Inc. ("Five Prime" or the "Company") (NASDAQ: FPRX) in connection with the proposed acquisition of the Company by Amgen Inc. (NASDAQ: AMGN). The transaction is structured as an all-cash tender offer pursuant to which the Company's shareholders will receive $38.00 for each share of Five Prime common stock that they hold.
If you own Five Prime shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website:
Or please contact:
Joshua Rubin, Esq.
1500 Broadway, 16 th Floor
New York , NY 10036
WeissLaw LLP is investigating whether Five Prime's board acted in the best interest of Five Prime's public shareholders in agreeing to the proposed transaction, whether the $38.00 offer price adequately compensates Five Prime's shareholders, and whether all information regarding the process undertaken by the board and the valuation of the transaction will be fully and fairly disclosed to Five Prime's public shareholders.
WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties. We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases. If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at firstname.lastname@example.org
View original content to download multimedia: http://www.prnewswire.com/news-releases/shareholder-alert-weisslaw-llp-investigates-five-prime-therapeutics-inc-301240960.html
SOURCE WeissLaw LLP